These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3887213)

  • 21. Pergolide and lisuride for Parkinson's disease.
    Lieberman AN; Leibowitz M; Neophytides A; Kupersmith M; Mehl S; Kleinberg D; Serby M; Goldstein M
    Lancet; 1979 Nov; 2(8152):1129-30. PubMed ID: 91856
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 23. Pergolide mesylate: new therapy for Parkinson disease.
    Tanner CM; Klawans HL
    Ann Intern Med; 1982 Apr; 96(4):522-3. PubMed ID: 7065569
    [No Abstract]   [Full Text] [Related]  

  • 24. Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
    Navan P; Bain PG
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):602-3. PubMed ID: 12397168
    [No Abstract]   [Full Text] [Related]  

  • 25. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease: new drugs help but no cure on the horizon.
    González ER
    JAMA; 1981 Jul; 246(1):11-2. PubMed ID: 7241717
    [No Abstract]   [Full Text] [Related]  

  • 27. Pergolide mesylate and idiopathic Parkinson disease.
    Tanner CM; Goetz CG; Glantz RH; Glatt SL; Klawans HL
    Neurology; 1982 Oct; 32(10):1175-9. PubMed ID: 6889702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease.
    Leibowitz M; Lieberman AN; Neophytides A; Gopinathan G; Goldstein M
    Adv Neurol; 1983; 37():121-30. PubMed ID: 6858770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1985; 8(3):260-5. PubMed ID: 3899352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.
    Koller WC; Diamond BI; Weiner WJ; Nausieda PA; Klawans HL
    Trans Am Neurol Assoc; 1979; 104():161-4. PubMed ID: 553398
    [No Abstract]   [Full Text] [Related]  

  • 32. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.
    Takahashi H; Nogawa S; Tachibana H; Kawamura J; Abe T; Ogino Y; Kashihara K; Hamada T; Kowa H;
    J Int Med Res; 2008; 36(1):106-14. PubMed ID: 18230274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up.
    Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I
    Eur J Neurol; 2004 Jul; 11(7):483-8. PubMed ID: 15257688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience of pergolide in the treatment of Chinese parkinsonian patients with dose-related fluctuations.
    Shan DE; Yeh SI
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):312-8. PubMed ID: 8605645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Optimum dosage of pergolide in patients with Parkinson's disease].
    Neshige R
    Rinsho Shinkeigaku; 2005 Apr; 45(4):328-30. PubMed ID: 15912805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pergolide in the treatment of Parkinson's disease.
    Mear JY; Barroche G; de Smet Y; Weber M; Lhermitte F; Agid Y
    Neurology; 1984 Jul; 34(7):983-6. PubMed ID: 6539880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pergolide in Parkinson's disease.
    Goetz CG; Tanner CM; Glantz R; Klawans HL
    Arch Neurol; 1983 Dec; 40(13):785-7. PubMed ID: 6639407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pergolide therapy in Parkinson's disease.
    Jeanty P; Van den Kerchove M; Lowenthal A; De Bruyne H
    J Neurol; 1984; 231(3):148-52. PubMed ID: 6481422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 40. Double-blind trial of pergolide for Parkinson's disease.
    Diamond SG; Markham CH; Treciokas LJ
    Neurology; 1985 Mar; 35(3):291-5. PubMed ID: 3883232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.